Abstract: The invention discloses a functionalised chitosan, or a salt thereof, used in the treatment of pathologies of the respiratory tract or hepatic pathologies, preferably caused by viral infections. It was indeed observed that said functionalised chitosan or salt thereof was able to act as galectin-modulator, modulating in particular galectin-3, and therefore determining a marked reduction in the inflammatory and fibrotic cascade generated by these viral infections. The invention moreover discloses a pharmaceutical composition, as well as a biomaterial, comprising this functionalised chitosan, or a salt thereof.

Abstract: A crosslinked polymer of functionalized hyaluronic acid, or derivative thereof, is disclosed, as well as a process for its preparation and its use as a biomaterial and as an ingredient in pharmaceutical compositions. The use of this crosslinked polymer in the treatment of disorders ascribable to altered galectin expression, is also disclosed.

Abstract: The present invention discloses a functionalized hyaluronic acid or a derivative thereof, as well as a process for the preparation thereof, and the use thereof as a biomaterial and as an ingredient in pharmaceutical compositions. The present invention furthermore discloses the use of said functionalized hyaluronic acid or a derivative thereof in the treatment of pathologies ascribable to altered galectin expression.

Abstract: A neutral salt consisting of a polyaminosaccharide cation and an anion, as well as a procedure for the preparation of the neutral salt and uses thereof as a biomaterial and as an ingredient in pharmaceutical compositions are disclosed. Indeed, said neutral salt has surprisingly exhibited high water-solubility and high purity, the preparation procedure having minimised the content of high-risk contaminants in the final product and reduced reaction and purification times.

Abstract: The present application describes polysaccharide compositions that can be used as modulators of cell proliferation processes and their use in tissue repair with fibrotic process inhibition. These modulation properties can be usefully used in tissue repair for the prevention of fibrotic processes and/or tissue adhesions in traumatic, post-surgical and chronic fibrotic processes associated to autoimmune diseases.

Abstract: The present invention discloses a functionalized hyaluronic acid or a derivative thereof, as well as a process for the preparation thereof, and the use thereof as a biomaterial and as an ingredient in pharmaceutical compositions. The present invention furthermore discloses the use of said functionalized hyaluronic acid or a derivative thereof in the treatment of pathologies ascribable to altered galectin expression.

Abstract: The present invention concerns new compositions containing hyaluronic acid or the derivatives thereof in association with the proteolytic enzyme collagenase (and relative pharmaceutical formulations) for the preparation of a dressing for topical treatment of various kinds of wounds, burns of varying depth, pressure sores, vascular ulcers and diabetic foot ulcers as well as for the treatment of hypertrophic and keloid scars.

Abstract: A neutral salt consisting of a polyaminosaccharide cation and an anion, as well as a procedure for the preparation of the neutral salt and uses thereof as a biomaterial and as an ingredient in pharmaceutical compositions are disclosed. Indeed, said neutral salt has surprisingly exhibited high water-solubility and high purity, the preparation procedure having minimised the content of high-risk contaminants in the final product and reduced reaction and purification times.

Abstract: The present application describes polysaccharide compositions that can be used as modulators of cell proliferation processes and their use in tissue repair with fibrotic process inhibition. These modulation properties can be usefully used in tissue repair for the prevention of fibrotic processes and/or tissue adhesions in traumatic, post-surgical and chronic fibrotic processes associated to autoimmune diseases.

Abstract: The present invention discloses a pharmaceutical composition comprising at least one bioactive substance and at least one neutral salt consisting of a polyamino-saccharide cation and an anion, for use in the treatment of articular tissues affected by arthropathies, wherein said pharmaceutical composition reduces expression of the key receptors involved in the genesis the inflammatory cascade and efficaciously maintains performance for a prolonged period of time.

Abstract: The present application describes compositions that can be used for the controlled release of pharmacological active ingredients from a viscoelastic aqueous polysaccharide matrix, and their potential use in the treatment of different stages of musculoskeletal diseases. The combination of drug release modulation and the viscoelastic nature of the composition makes possible the use thereof in the treatment of acute and chronic phases of musculoskeletal diseases characterized by an inflammatory state, and where a therapeutic effect and a viscosupplemental contribution are required.

Abstract: The present invention concerns new compositions containing hyaluronic acid or the derivatives thereof in association with the proteolytic enzyme collagenase (and relative pharmaceutical formulations) for the preparation of a dressing for topical treatment of various kinds of wounds, burns of varying depth, pressure sores, vascular ulcers and diabetic foot ulcers as well as for the treatment of hypertrophic and keloid scars.

Abstract: The present invention concerns new compositions containing hyaluronic acid or the derivatives thereof in association with the proteolytic enzyme collagenase (and relative pharmaceutical formulations) for the preparation of a dressing for topical treatment of various kinds of wounds, burns of varying depth, pressure sores, vascular ulcers and diabetic foot ulcers as well as for the treatment of hypertrophic and keloid scars.

Abstract: This invention relates to oral and intra-articular formulations based on sulphated hyaluronic acid which are effective in the treatment of degenerative osteoarthritis.

Abstract: The present invention concerns new compositions containing hyaluronic acid or the derivatives thereof in association with the proteolytic enzyme collagenase (and relative pharmaceutical formulations) for the preparation of a dressing for topical treatment of various kinds of wounds, burns of varying depth, pressure sores, vascular ulcers and diabetic foot ulcers as well as for the treatment of hypertrophic and keloid scars.

Abstract: The present invention concerns new compositions containing hyaluronic acid or the derivatives thereof in association with the proteolytic enzyme collagenase (and relative pharmaceutical formulations) for the preparation of a dressing for topical treatment of various kinds of wounds, burns of varying depth, pressure sores, vascular ulcers and diabetic foot ulcers as well as for the treatment of hypertrophic and keloid scars.

Abstract: There is described a new non-woven fabric produced with the electrospinning technique, and the use thereof as new biomaterial for the biomedical and surgical field.

Abstract: This invention relates to oral and intra-articular formulations based on sulphated hyaluronic acid which are effective in the treatment of degenerative osteoarthritis.

Abstract: The present invention regards a biological material comprising: a) a liquid carrier comprising a viscous solution containing at least one natural and/or semisynthetic polysaccharide, and having a Dynamic viscosity measured at 20° C. and at shear rate of D=350 s?1, comprised between 100 and 250 c Poise and/or a Kinematic viscosity comprised between 99 and 248 cSt (measured at the same conditions); b) a culture of mesenchymal stem cells, and/or c) a platelet-rich hemo-derivative. This type of material in form of viscous liquid is particularly suitable for the therapy of osteoarthrosis, ligament damage, in particular tendon and cartilage damage) and may be administered intra-articularly, intradermally or directly applied in situ without altering the properties of the mesenchymal stem cells and/or platelets contained therein.

Abstract: This invention relates to oral and intra-articular formulations based on sulphated hyaluronic acid which are effective in the treatment of degenerative osteoarthritis.